Optimizing immunotherapy in high-risk lymphoma

优化高危淋巴瘤的免疫治疗

• 批准号: 371068
• 负责人: Johnson Nathalie
• 金额: $ 88.05万
• 依托单位: Lady Davis Institute for Medical Research (Mtl)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-09-01 至 2022-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=371068&lang=en
• 关键词: Circulating Tumour Dna; Dlbcl; Follicular Lymphoma; Hodgkin; Immunotherapy; Jak/Stat; Lymphoma; Pd1; Sequencing

Drs Johnson, Decaluwe and Morin want to develop a novel way of monitoring patients with lymphoma and find a new immunotherapy regimen that would be effective in patients that are not cured with conventional chemotherapy. They will first genetically profi

约翰逊、德卡鲁韦和莫林博士希望开发一种新的方法来监测淋巴瘤患者，并找到一种新的免疫治疗方案，对常规化疗无法治愈的患者有效。 他们首先会从基因上获利，